🚀 VC round data is live in beta, check it out!
Artiva Biotherapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Artiva Biotherapeutics and similar public comparables like vTv Therapeutics, Mayne Pharma Group, Adagene, Tetratherix and more.
Artiva Biotherapeutics Overview
About Artiva Biotherapeutics
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
Founded
2019
HQ
Employees
89
Website
Sectors
Financials (LTM)
EV
$31M
Artiva Biotherapeutics Financials
Artiva Biotherapeutics reported last 12-month revenue of —.
In the same LTM period, Artiva Biotherapeutics generated — in gross profit and had net loss of ($86M).
Revenue (LTM)
Artiva Biotherapeutics P&L
In the most recent fiscal year, Artiva Biotherapeutics reported revenue of $251K and EBITDA of ($65M).
Artiva Biotherapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $251K | XXX | XXX | XXX |
| EBITDA | — | XXX | ($65M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (25837%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (26806%) | XXX | XXX | XXX |
| Net Profit | ($86M) | XXX | ($69M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (27566%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Artiva Biotherapeutics Stock Performance
Artiva Biotherapeutics has current market cap of $142M, and enterprise value of $31M.
Market Cap Evolution
Artiva Biotherapeutics' stock price is $5.79.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $31M | $142M | 0.0% | XXX | XXX | XXX | $-2.82 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialArtiva Biotherapeutics Valuation Multiples
Artiva Biotherapeutics trades at 122.9x EV/Revenue multiple, and (0.5x) EV/EBITDA.
EV / Revenue (LTM)
Artiva Biotherapeutics Financial Valuation Multiples
As of March 18, 2026, Artiva Biotherapeutics has market cap of $142M and EV of $31M.
Equity research analysts estimate Artiva Biotherapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Artiva Biotherapeutics has a P/E ratio of (1.6x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $142M | XXX | $142M | XXX | XXX | XXX |
| EV (current) | $31M | XXX | $31M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 122.9x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (0.5x) | XXX | XXX | XXX |
| EV/EBIT | (0.3x) | XXX | (0.5x) | XXX | XXX | XXX |
| P/E | (1.6x) | XXX | (2.1x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (0.6x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Artiva Biotherapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Artiva Biotherapeutics Margins & Growth Rates
Artiva Biotherapeutics' revenue in the last fiscal year declined by (100%).
Artiva Biotherapeutics' revenue per employee in the last FY averaged $0.0M.
Artiva Biotherapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (100%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (25837%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 128% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 6855% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 20051% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 26906% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Artiva Biotherapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| vTv Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Mayne Pharma Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Adagene | XXX | XXX | XXX | XXX | XXX | XXX |
| Tetratherix | XXX | XXX | XXX | XXX | XXX | XXX |
| Mersana Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Artiva Biotherapeutics M&A Activity
Artiva Biotherapeutics acquired XXX companies to date.
Last acquisition by Artiva Biotherapeutics was on XXXXXXXX, XXXXX. Artiva Biotherapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Artiva Biotherapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialArtiva Biotherapeutics Investment Activity
Artiva Biotherapeutics invested in XXX companies to date.
Artiva Biotherapeutics made its latest investment on XXXXXXXX, XXXXX. Artiva Biotherapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Artiva Biotherapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Artiva Biotherapeutics
| When was Artiva Biotherapeutics founded? | Artiva Biotherapeutics was founded in 2019. |
| Where is Artiva Biotherapeutics headquartered? | Artiva Biotherapeutics is headquartered in United States. |
| How many employees does Artiva Biotherapeutics have? | As of today, Artiva Biotherapeutics has over 89 employees. |
| Who is the CEO of Artiva Biotherapeutics? | Artiva Biotherapeutics' CEO is Fred Aslan. |
| Is Artiva Biotherapeutics publicly listed? | Yes, Artiva Biotherapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Artiva Biotherapeutics? | Artiva Biotherapeutics trades under ARTV ticker. |
| When did Artiva Biotherapeutics go public? | Artiva Biotherapeutics went public in 2024. |
| Who are competitors of Artiva Biotherapeutics? | Artiva Biotherapeutics main competitors are vTv Therapeutics, Mayne Pharma Group, Adagene, Tetratherix. |
| What is the current market cap of Artiva Biotherapeutics? | Artiva Biotherapeutics' current market cap is $142M. |
| What is the current revenue growth of Artiva Biotherapeutics? | Artiva Biotherapeutics revenue growth (vs. last FY) is (100%). |
| What is the current EV/Revenue multiple of Artiva Biotherapeutics? | Current revenue multiple of Artiva Biotherapeutics is 122.9x. |
| Is Artiva Biotherapeutics profitable? | No, Artiva Biotherapeutics is not profitable. |
| What is the current net income of Artiva Biotherapeutics? | Artiva Biotherapeutics' last 12 months net income is ($86M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.